Dermatology | Preclinical Developments

Krystal Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications

Lead Product(s): KB301

Therapeutic Area: Dermatology Product Name: KB301

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2020

Details:

KB301 is designed to restore collagen homeostasis locally via directed COL3A1 expression, thereby reconstructing an optimal physiologic environment in the skin to treat wrinkles and other superficial skin defects.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutic Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis

Lead Product(s): Antibiotic,Zinc chelator

Therapeutic Area: Dermatology Product Name: BioLexa

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 13, 2020

Details:

Study to determine the safety, tolerability, pharmacokinetics and efficacy of twice daily application of topical BioLexa in healthy subjects and patients with mild to moderate atopic dermatitis.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Executes Licensing Agreement with Isoprene Pharmaceuticals of VNLG-152 for Treatment of Dermatological Diseases

Lead Product(s): VNLG 152

Therapeutic Area: Dermatology Product Name: VNLG 152

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Isoprene Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 31, 2020

Details:

Isoprene Pharmaceuticals will acquire rights to Hoth's VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases.

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $2,000.0 million Upfront Cash: $150.0 million

Deal Type: Partnership July 09, 2020

Details:

Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter. Sanofi will lead all clinical development activities for the second program.

Aclaris Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777

Lead Product(s): ATI-1777

Therapeutic Area: Dermatology Product Name: ATI-1777

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

Aclaris plans to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University

Lead Product(s): WEG232

Therapeutic Area: Dermatology Product Name: WEG232

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: George Washington University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

Hoth Therapeutics has expanded its research agreement with the George Washington University to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Lead Product(s): VNLG 152

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

Management provides pipeline update for assets including BioLexa Platform (Dermatological), VNLG-152 (Dermatological), WEG-232 (Dermatological), VaxCelerate (COVID-19), Novel Peptide Therapeutic (COVID-19), AEA-loaded Z-pods™ (Lupus), Exon Skipping Approach (Allergic Disease).

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

Kymera is developing potent and selective orally administered IRAK4 degraders for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven autoimmune and autoinflammatory diseases.

Chelexa Biosciences

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

Lead Product(s): Antimicrobial therapy

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Hoth Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 18, 2020

Details:

Hoth Therapeutics has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, antimicrobial therapy focused on treating atopic dermatitis. The agreement is an extension to the previously executed sublicense agreement with Chelexa Biosciences.

Tetra BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Tetra Receives its 4th FDA Orphan Drug Designation

Lead Product(s): Tetrahydrocannabinol,Cannabidiol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

PP004 will be used for management of pain and itch in EB, symptoms that, despite a range of current treatment strategies, significantly affect the quality of life in EB patients.

Find

Find Novel Dermatology Drugs in Preclinical Development

Preclinical

Product Type

Companies

Krystal Biotech

Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications

Hoth Therapeutics

Hoth Therapeutic Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis

Hoth Therapeutics

Hoth Therapeutics Executes Licensing Agreement with Isoprene Pharmaceuticals of VNLG-152 for Treatment of Dermatological Diseases

Kymera Therapeutics

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

Aclaris Therapeutics

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777

Hoth Therapeutics

Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University

Hoth Therapeutics

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Kymera Therapeutics

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis

Chelexa Biosciences

Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

Tetra BioPharma

Tetra Receives its 4th FDA Orphan Drug Designation